Insight Molecular Diagnostics (NASDAQ: OCX) shares H1 2025 financial results via press release

Rhea-AI Filing Summary

Insight Molecular Diagnostics Inc. filed a current report to state that it released a press release with its financial results for the six months ended June 30, 2025. The company explains that the press release, dated August 11, 2025 and attached as Exhibit 99.1, contains details on its results of operations and financial condition for that period. The information in this section is furnished rather than filed, meaning it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings unless specifically referenced.

false 0001642380 0001642380 2025-08-11 2025-08-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2025

Insight Molecular Diagnostics Inc.

(Exact name of Registrant as specified in its charter)

California		1-37648		27-1041563
(State or other jurisdiction of incorporation)		(Commission File No.)		(IRS Employer Identification No.)

2 International Plaza Dr., Suite 510

Nashville, Tennessee 37217

(Address of principal executive offices) (Zip code)

(615) 255-8880

Registrant’s telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, no par value		IMDX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 11, 2025, Insight Molecular Diagnostics Inc. (“we,” “us,” “our,” the “Company” or “iMDx”) issued a press release announcing our financial results for the six months ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1, which, in its entirety, is incorporated herein by reference.

The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as otherwise expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press release dated August 11, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INSIGHT MOLECULAR DIAGNOSTICS INC.
Date: August 11, 2025	By:	/s/ Peter Hong
	Name:	Peter Hong
	Title:	Vice President, General Counsel

FAQ

What did Insight Molecular Diagnostics Inc. (OCX) disclose in this 8-K?

The company disclosed that it issued a press release announcing its financial results for the six months ended June 30, 2025, and furnished that release as Exhibit 99.1.

Which period do the reported results for Insight Molecular Diagnostics Inc. (OCX) cover?

The results discussed in the press release cover the six-month period ended June 30, 2025.

Where can investors find the detailed financial results for Insight Molecular Diagnostics Inc. (OCX)?

Detailed financial results are contained in the press release furnished as Exhibit 99.1 to this report.

Is the financial information for Insight Molecular Diagnostics Inc. (OCX) considered filed or furnished?

The company states that the information in Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act.

Who signed the Insight Molecular Diagnostics Inc. (OCX) report and in what capacity?

The report was signed on behalf of the company by Peter Hong, who is identified as Vice President and General Counsel.

What exhibits are included with this Insight Molecular Diagnostics Inc. (OCX) report?

The report lists Exhibit 99.1, the press release dated August 11, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.